Clinical trial · Interventional
The Role of Follicle Stimulating Hormone in Advanced Prostate Cancer
Case Control Study Regarding the Role of Follicle Stimulating Hormone in Chemically Castrated Young Men
NCT04134130CI-TRIAL-00042920completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In order to elucidate if FSH can have testosterone like effects, samples from young, non-smoking healthy volunteers, with normal body mass index, and with pharmacologically induced gonadotropin deficiency will be studied regarding their capacity to induce prostate specific antigen (PSA), which normally is regulated by testosterone.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer Recurrent | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Degarelix 120 MG [Firmagon] | Drug | Degarelix | ALIAS |
| Gonal F RFF Pen 900 UNT Per 1.5 ML Pen Injector | Drug | — | UNRESOLVED |
| Testosterone Undecanoate | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- OTHER
- label
- GnRH antagonist + FSH + testosterone
- description
- At the start of the study: 240 mg of the gonadotropin releasing hormone antagonist Degarelix (Ferring GmbH, Wittland, Kiel, Germany) + recombinant FSH (Gonal-f, Merck Serrono S.A. Aubonne, Schweiz), 300 IU every second day for 5 weeks. After 3 weeks: 1000 mg testosterone once.
- interventionNames
- Drug: Degarelix 120 MG [Firmagon]
- Drug: Gonal F RFF Pen 900 UNT Per 1.5 ML Pen Injector
- Drug: Testosterone Undecanoate
- type
- OTHER
- label
- GnRH antagonist + testosterone
- description
- At the start of the study: 240 mg of the gonadotropin releasing hormone antagonist Degarelix (Ferring GmbH, Wittland, Kiel, Germany). After 3 weeks: 1000 mg testosterone (Nebido, Bayer AB, Solna, Sweden) once.
- interventionNames
- Drug: Degarelix 120 MG [Firmagon]
- Drug: Testosterone Undecanoate
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 20 Years
- Maximum age
- 30 Years
Show eligibility criteria text
Inclusion Criteria: Healthy, non-smoking, body mass index 20-25, Exclusion Criteria: Medication or drug abuse \-
References
Publications (0)
Data not yet available
No reference posted for this study.